SCHEMBL377397

SCHEMBL377397

NC(C(=O)O)(c1cccc(C(F)(F)F)c1)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.50
MAPT P10636 2/20 0.46
SRD5A2 P31213 1/20 0.46
MEN1 O00255 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.45
P2RX1 P51575 1/20 0.44
LMNA P02545 1/20 0.44
GRM2 Q14416 1/20 0.43
GRM3 Q14832 1/20 0.43
HTR3E A5X5Y0 1/20 0.42
HTR3B O95264 1/20 0.42
HTR3A P46098 1/20 0.42
HTR3D Q70Z44 1/20 0.42
HTR3C Q8WXA8 1/20 0.42
KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10140922 0.86 CES2 (0.50) CES2MAPTSRD5A2MEN1HTT
SCHEMBL30605754 0.79 CYP1A2 (0.59) CES2MAPTSRD5A2MEN1HTT
SCHEMBL382497 0.79 CYP1A2 (0.59) CES2MAPTSRD5A2MEN1HTT
SCHEMBL715409 0.79 CYP1A2 (0.59) CES2MAPTSRD5A2MEN1HTT
SCHEMBL717446 0.79 CYP1A2 (0.59) CES2MAPTSRD5A2MEN1HTT
Hydrochloric Acid SCHEMBL28437808 0.77 CYP1A2 (0.58) CES2MAPTSRD5A2MEN1HTT
Hydrochloric Acid SCHEMBL717267 0.77 CYP1A2 (0.58) CES2MAPTSRD5A2MEN1HTT
SCHEMBL23972372 0.77 CES2 (0.57) CES2MAPTSRD5A2MEN1HTT
SCHEMBL3172058 0.76 CES2 (0.55) CES2MAPTSRD5A2MEN1HTT
Benzene SCHEMBL8568955 0.76 TSHR (0.67) CES2MAPTSRD5A2MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2408754-B1 TRIAZOLE DERIVATIVES AS INHIBITORS OF THE VASOPRESSIN RECEPTOR FOR THE TREATMENT OF CARDIAC INSUFFICIENCY BAYER IP GMBH (DE) 2013-10-09 EP disclosed
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-01 US disclosed
EP-2408754-A1 Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency Bayer Pharma Aktiengesellschaft (DE) 2012-01-25 EP disclosed
WO-2010105750-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053218-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY AVPR2, AVPR1B, AVPR1A CES2 3566/4885MAPT 4521/4885SRD5A2 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.